Polarean Imaging PLC Director dealings (5783O)
October 11 2021 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 5783O
Polarean Imaging PLC
11 October 2021
Polarean Imaging Plc
("Polarean" or the "Company")
Director dealing
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with a proprietary drug-device combination product,
announces that it was notified that the following Directors have
purchased ordinary shares ("Ordinary Shares") which are summarised
in the table below.
Director Number of Ordinary Shares Price per Ordinary Share
purchased
Richard Hullihen 153,060 47p
-------------------------- -------------------------
Cyrille Petit 150,000 53p
-------------------------- -------------------------
Jonathan Allis 150,000 53p
-------------------------- -------------------------
Following this Transactions, Mr Hullihen holds a beneficial
interest in 3,201,959 Ordinary Shares, representing 1.5 per cent.
of the Company's issued share capital with voting rights. Mr Petit
holds a beneficial interest in 584,000 Ordinary Shares,
representing 0.3 per cent. of the Company's issued share capital
with voting rights. Mr Allis holds a beneficial interest in
2,743,129 Ordinary Shares, representing 1.3 per cent. of the
Company's issued share capital with voting rights.
Notifications have been made in accordance with the requirements
of the EU Market Abuse Regulation in respect of the PDMRs and
further details can be found by following this link:
https://www.polarean-ir.com/content/investors/shareholder-information
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Jonathan Allis, Chairman
Stifel Nicolaus Europe Limited (NOMAD and +44 (0)20 7710
Sole Corporate Broker) 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea
(Healthcare Investment Banking)
Nick Adams / Fred Walsh (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44
(0)7879 741 001
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution functional
magnetic resonance imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate and less harmful to the patient
than current methods. The annual burden of pulmonary disease in the
US is estimated to be over US$150 billion.
The Group also develops and manufactures high performance MRI
radiofrequency (RF) coils which are a required component for
imaging (129) Xe in the MRI system. The development of these coils
by the Group facilitates the adoption of the Xenon technology by
providing application-specific RF coils which optimise the imaging
of (129) Xe in MRI equipment for use as a medical diagnostic as
well as a method of monitoring the efficacy of therapeutic
intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGPGBAUUPGGBU
(END) Dow Jones Newswires
October 11, 2021 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024